Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay

The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay.

Calcium channel blockers reverse muscle weakness in animal model of myotonic dystrophy type 1

New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel

January 3, 2024

Hallucinations and nightmares could herald the onset of autoimmune diseases

An increase in nightmares and hallucinations – or ‘daymares’ – could herald the onset of autoimmune diseases such as lupus, say an international team led

May 21, 2024

Gut microbiota could affect the responsiveness and efficacy of cancer treatment

A vast number of microbes colonizes the human body to form an ecological community known as the microbiota. Microbiota are made up of bacteria, viruses,

August 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.